Arbutus Biopharma

Arbutus Biopharma (pronunciation: /ɑːrˈbjuːtəs baɪoʊˈfɑːrmə/) is a biopharmaceutical company that focuses on discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (HBV).

Etymology

The name "Arbutus" is derived from the Latin Arbutus unedo, a species of tree known for its resilience and longevity, symbolizing the company's commitment to developing a cure for chronic hepatitis B. "Biopharma" is a portmanteau of "biological" and "pharmaceutical", indicating the company's focus on drug development using biological systems.

History

Arbutus Biopharma was founded in 2007 as Tekmira Pharmaceuticals. In 2015, Tekmira merged with OnCore Biopharma to form Arbutus Biopharma, with a renewed focus on developing a cure for chronic hepatitis B.

Research and Development

Arbutus Biopharma's research and development efforts are primarily focused on the discovery and development of drugs that can inhibit the replication of the hepatitis B virus and provide a cure for chronic hepatitis B infection. The company's pipeline includes a range of drug candidates, including RNA interference (RNAi) therapeutics, capsid inhibitors, and immune modulators.

Related Terms

External links

Medical encyclopedia article on Arbutus Biopharma
Wikipedia's article - Arbutus Biopharma

This WikiMD dictionary article is a stub. You can help make it a full article.

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski

Arbutus Biopharma